Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celltrion, Inc.

http://www.celltrion.com

Latest From Celltrion, Inc.

Celltrion Extends Remsima SC Indications

Celltrion has received a positive opinion from the CHMP for five additional indications for its Remsima SC biosimilar, expanding the scope of the subcutaneous infliximab product that was launched earlier this year.

Biosimilars Europe

Vertex's Triple CF Combo Gets EU Approval Nod; Rejection For Daiichi Sankyo

EU approval is likely for the eight medicines that got the thumbs up this week from the European Medicines Agency's drug evaluation committee, the CHMP. The panel held fire on one product it had been considering and also issued its first rejection of 2020.

Drug Review Europe

Coronavirus Update: Vaccine Developers Search For Exposed Patients, Celltrion's Infliximab Shows Promise

As a handful of frontrunners prepare to start Phase III trials of their COVID-19 vaccine candidates, enrolling patients who are likely to be exposed to the virus is of crucial importance.

Coronavirus COVID-19 Vaccines

Sun And Hikma Strike Ilumya Deal

Sun has inked another commercial partnership to bring psoriasis drug Ilumya to countries outside India, this time teaming with Hikma in the MENA region.

Deals Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Bio CDMO
    • Celltrion Healthcare Hungary Kft
UsernamePublicRestriction

Register